MAGL Inhibitor Compound 23 – 5 mg

Brand:
Cayman
CAS:
2324160-91-8
Storage:
-20
UN-No:
Non-Hazardous - /

MAGL inhibitor compound 23 is an inhibitor of monoacylglycerol lipase (MAGL; IC50 = 80 nM).{42789} It is selective for MAGL over cannabinoid receptor 1 (CB1), CB2, fatty acid amide hydrolase (FAAH), α/β-hydrolase domain-containing protein 6 (ABHD6), and ABHD12 (IC50s = >10 μM). MAGL inhibitor compound 23 inhibits the growth of HCT116, MDA-MB-231, Caov-3, OVCAR-3, and SKOV3 cells (IC50s = 21, 7.9, 25, 57, and 15 μM, respectively) but not MRC5 cells (IC50 = >100 μM). It increases the levels of 2-arachidonoyl glycerol (2-AG; Item No. 62160) in mouse brain and plasma when administered at a dose of 50 mg/kg.  

 

Available on backorder

SKU: 27348 - 5 mg Category:

Description

An inhibitor of MAGL (IC50 = 80 nM); selective for MAGL over CB1, CB2, FAAH, ABHD6, and ABHD12 (IC50s = >10 μM); inhibits the growth of HCT116, MDA-MB-231, Caov-3, OVCAR-3, and SKOV3 cells (IC50s = 21, 7.9, 25, 57, and 15 μM, respectively) but not MRC5 cells (IC50 = >100 μM); increases the levels of 2-AG in mouse brain and plasma at 50 mg/kg


Formal name: (1-(2-fluoro-5-hydroxybenzoyl)piperidin-4-yl)(4-isopropylphenyl)methanone

Synonyms: 

Molecular weight: 369.4

CAS: 2324160-91-8

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors|Glycerolipid Lipases||Research Area|Cancer||Research Area|Lipid Biochemistry|Endocannabinoid/Endocannabinoid-like||Research Area|Lipid Biochemistry|Glycerolipids|Lipases||Research Area|Neuroscience|Cannabinoid Research|Endocannabinoids